The NCCN, a not-for-profit network of 21 US cancer research centres, said it would be testing the drugs as treatment for hematologic malignancies and solid tumors, respectively.
Jeffery Bloss, GSK’s VP of oncology drug development, said the funding “will help expand the research and knowledge base of GSK Oncology’s newer cancer therapies.”
The two pharmaceuticals, branded as Arzerra and Votrient, are already approved by the US Food and Drug Administration (FDA) and generated around £13m (€15.5m) each last year according to GSK’s annual results.